GENNEX.BO · BSE
GENNEX LABORATORIES LTD.
₹10.32
+1.08% (+₹0.11)
Prev. close
₹10.21
Volume
1,51,130
As of
23 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About GENNEX LABORATORIES LTD.
Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin; and Allopurinol, a xanthine oxidase inhibitor. It has operations in India, Algeria, Bangladesh, Barzil, Bolivia, Colombia, the Czech Republic, Egypt, El Salvador, Germany, Guatemala City, Mexico, Peru, Spain, Turkey, Thailand, the United Arab Emirates, and Vietnam. Gennex Laboratories Limited was formerly known as Prudential Pharmaceuticals Limited and changed its name to Gennex Laboratories Limited in September 2007. Gennex Laboratories Limited was incorporated in 1985 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Arihant Baid
Headquarters
Hyderabad
Employees
125
Website
gennexlab.comExchange
View on BSE ↗Key stats
Market cap
₹250.72 Cr
P/E ratio (TTM)
12.3
EPS (TTM)
₹0.84
Beta (1Y · daily vs NIFTY 50)
1.52
Beta (5Y · monthly vs NIFTY 50)
1.55
Shares float
17.00 Cr
EPS · quarter ended Jun 2026
₹0.19
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 1.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹59.65 Cr | ₹61.21 Cr | ₹64.96 Cr | ₹79.10 Cr | ₹137.55 Cr | ₹172.75 Cr | |
| EBITDA | ₹7.06 Cr | ₹6.76 Cr | ₹8.65 Cr | ₹21.94 Cr | ₹27.15 Cr | ₹30.68 Cr |
| ₹4.04 Cr | ₹3.92 Cr | ₹4.92 Cr | ₹13.18 Cr | ₹18.12 Cr | ₹20.98 Cr | |
| Diluted EPS | — | — | ₹0.32 | ₹0.61 | ₹0.78 | ₹0.87 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹132.32 Cr | ₹229.99 Cr | ₹256.04 Cr | ₹348.68 Cr | |
| — | — | ₹17.34 Cr | ₹18.94 Cr | ₹27.11 Cr | ₹79.36 Cr | |
| Stockholders' equity | — | — | ₹80.35 Cr | ₹170.38 Cr | ₹186.69 Cr | ₹222.52 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹23.68 Cr | ₹-46.69 Cr | ₹-10.80 Cr | ₹-63.65 Cr | |
| Investing cash flow | — | — | ₹-38.33 Cr | ₹18.91 Cr | ₹82.37 L | ₹-4.80 Cr |
| — | — | ₹21.03 Cr | ₹73.68 Cr | ₹4.57 Cr | ₹65.30 Cr | |
| Capital expenditure | — | ₹-1.59 Cr | ₹-39.79 Cr | — | ₹-8.95 Cr | ₹-11.94 Cr |
| End cash position | — | — | ₹15.06 Cr | ₹60.98 Cr | ₹55.57 Cr | ₹52.42 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| GENNEX LABORATORIES LTD. | ₹249.75 Cr | ₹10.28 | 12.2 | 1.12 | 9.4% | 0.36 | +25.6% | -17.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 24
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Gennex Laboratories Share Price Up 10.09%: Full Analysis
Gennex Laboratories Ltd. shares rose 10.09% to Rs 12.88, increasing its market capitalization to Rs 285.95 crore. This move positioned the micro-cap stock among today's notable gainers. The company's P/E ratio is 14.66 and P/B ratio is 1.25, with an ROE of 10.71%.
Gennex Laboratories consolidated net profit declines 5.88% in the June 2026 quarter
Business Standard · 1 month ago